Lessons learned from early-stage clinical trials for diabetic nephropathy.
Expert Opin Investig Drugs
; 33(4): 287-301, 2024 Apr.
Article
in En
| MEDLINE
| ID: mdl-38465470
ABSTRACT
INTRODUCTION:
The evolution of treatment for diabetic nephropathy illustrates how basic biochemistry and physiology have led to new agents such as SGLT2 inhibitors and mineralocorticoid blockers. Conversely, clinical studies performed with these agents have suggested new concepts for investigational drug development. We reviewed currently available treatments for diabetic nephropathy and then analyzed early clinical trials of new agents to assess the potential for future treatment modalities. AREAS COVERED We searched ClinicalTrials.gov for new agents under study for diabetic nephropathy in the past decade. Once we have identified investigation trials of new agents, we then used search engines and Pubmed.gov to find publications providing insight on these drugs. Current treatments have shown benefit in both cardiac and renal disease. In our review, we found 51 trials and 43 pharmaceuticals in a number of drug classes mineralocorticoid blockers, anti-inflammatory, anti-fibrosis, nitric oxide stimulatory, and podocyte protection, and endothelin inhibitors. EXPERT OPINION It is difficult to predict which early phase treatments will advance to confirmatory clinical trials. Current agents are thought to improve hemodynamic function. However, the coincident benefit of both myocardial function and the glomerulus argues for primary effects at the subcellular level, and we follow the evolution of agents which modify fundamental cellular processes.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Diabetes Mellitus
/
Diabetic Nephropathies
/
Sodium-Glucose Transporter 2 Inhibitors
Limits:
Humans
Language:
En
Journal:
Expert Opin Investig Drugs
Journal subject:
TERAPIA POR MEDICAMENTOS
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: